DASATINIB, Dasatinib, dasatinib, dasatinib
CA180-226
Phase 2 small_molecule active
Quick answer
DASATINIB, Dasatinib, dasatinib, dasatinib for Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active